A lung transplant is usually the final therapeutic
option for patients with respiratory insufficiency. In
spite of the many advances in immunology and the
management of complications, mortality and morbidity
associated with this transplant are far higher than
with others. Acute rejection is an almost universal
problem in the first year, while obliterative bronchitis
reduces long term survival. Respiratory infections
also play a significant role in the complications associated
with lung transplants due to the constant
exposure of the graft to the outside. However, the
success of this therapeutic option, which basically
depends on a suitable selection of donor and recipient,
are evident, above all with respect to quality of
life
